Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines.

Spyros ChalkiasNichole McGheeJordan L WhatleyBrandon EssinkAdam BroszJoanne E TomassiniBethany GirardDarin K EdwardsKai WuArshan NasirDiana LeeLaura E AvenaJing FengWeiping DengDavid C MontefioriLindsey R BadenJacqueline M MillerRituparna Das

Published in: The Journal of infectious diseases (2024)

XBB.1.5-containing mRNA-1273 vaccines elicit robust, diverse nAb responses against more recent SARS-CoV-2 variants including JN.1, supporting the XBB.1.5-spike sequence selection for the 2023-2024 COVID-19 vaccine update.

Keyphrases

sars cov
respiratory syndrome coronavirus
advanced non small cell lung cancer
coronavirus disease
binding protein
dna methylation
genome wide